Ambalavanan R, Snead R, Marczika J, Malioukis A
Front Public Health. 2024; 12:1347623.
PMID: 38414904
PMC: 10896918.
DOI: 10.3389/fpubh.2024.1347623.
Kuwahara B, Bauch C
Heliyon. 2024; 10(4):e25363.
PMID: 38370214
PMC: 10869765.
DOI: 10.1016/j.heliyon.2024.e25363.
Kiselev I, Akberdin I, Kolpakov F
Sci Rep. 2023; 13(1):13439.
PMID: 37596296
PMC: 10439236.
DOI: 10.1038/s41598-023-40008-9.
Zelenkov Y, Reshettsov I
Expert Syst Appl. 2023; 224:120034.
PMID: 37033691
PMC: 10072952.
DOI: 10.1016/j.eswa.2023.120034.
Yurina V, Rahayu Adianingsih O, Widodo N
Vaccine X. 2023; 13:100265.
PMID: 36712897
PMC: 9869617.
DOI: 10.1016/j.jvacx.2023.100265.
Knowledge, Attitude, and Acceptance of Sinopharm and AstraZeneca's COVID-19 Vaccines among Egyptian Population: A Cross-Sectional Study.
Boshra M, Elgendy M, Abdelaty L, Tammam M, Alanazi A, Alzarea A
Int J Environ Res Public Health. 2022; 19(24).
PMID: 36554688
PMC: 9778847.
DOI: 10.3390/ijerph192416803.
Changing patterns of SARS-CoV-2 infection through Delta and Omicron waves by vaccination status, previous infection and neighbourhood deprivation: a cohort analysis of 2.7 M people.
Green M, Hungerford D, Hughes D, Garcia-Finana M, Turtle L, Cheyne C
BMC Infect Dis. 2022; 22(1):889.
PMID: 36435775
PMC: 9701390.
DOI: 10.1186/s12879-022-07878-2.
Epidemiological model based periodic intervention policies for COVID-19 mitigation in the United Kingdom.
Rinaldi G, Menon P, Ferrara A, Strain W, Edwards C
Sci Rep. 2022; 12(1):15660.
PMID: 36123382
PMC: 9483909.
DOI: 10.1038/s41598-022-19630-6.
BNT162b2 Booster Vaccination Elicits Cross-Reactive Immunity Against SARS-CoV-2 Variants B.1.1.529 and B.1.617.2 in Convalescents of All Ages.
Jahrsdorfer B, Proffen M, Scholz J, Hagele J, Ludwig C, Vieweg C
Front Immunol. 2022; 13:920210.
PMID: 35795665
PMC: 9250979.
DOI: 10.3389/fimmu.2022.920210.
Need of booster vaccine doses to counteract the emergence of SARS-CoV-2 variants in the context of the Omicron variant and increasing COVID-19 cases: An update.
Mohapatra R, El-Shall N, Tiwari R, Nainu F, Kandi V, Sarangi A
Hum Vaccin Immunother. 2022; 18(5):2065824.
PMID: 35594528
PMC: 9897647.
DOI: 10.1080/21645515.2022.2065824.
Intranasal Lentiviral Vector-Mediated Antibody Delivery Confers Reduction of SARS-CoV-2 Infection in Elderly and Immunocompromised Mice.
Du Y, Zhang S, Zhang Z, Miah K, Wei P, Zhang L
Front Immunol. 2022; 13:819058.
PMID: 35529866
PMC: 9072863.
DOI: 10.3389/fimmu.2022.819058.
Estimating the Neutralizing Effect and Titer Correlation of Semi-Quantitative Anti-SARS-CoV-2 Antibody Immunoassays.
Lee B, Ko J, Park J, Moon H, Baek J, Jung S
Front Cell Infect Microbiol. 2022; 12:822599.
PMID: 35493733
PMC: 9046723.
DOI: 10.3389/fcimb.2022.822599.
Social network-based ethical analysis of COVID-19 vaccine supply policy in three Central Asian countries.
Aripov T, Wikler D, Asadov D, Tulekov Z, Murzabekova T, Munir K
BMC Med Ethics. 2022; 23(1):21.
PMID: 35264173
PMC: 8906360.
DOI: 10.1186/s12910-022-00764-1.
COVID-19 Recovery Patterns Across Alpha (B.1.1.7) and Delta (B.1.617.2) Variants of SARS-CoV-2.
Kumar N, Quadri S, AlAwadhi A, Alqahtani M
Front Immunol. 2022; 13:812606.
PMID: 35237265
PMC: 8882843.
DOI: 10.3389/fimmu.2022.812606.
T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
Cohen H, Rotem S, Elia U, Bilinsky G, Levy I, Chitlaru T
Viruses. 2022; 14(2).
PMID: 35215940
PMC: 8878189.
DOI: 10.3390/v14020347.
Eight Good Reasons for Careful Monitoring and Evaluation of the Vaccine Campaign against COVID-19: Lessons Learned through the Lombardy Experience for Dealing with Next Challenges.
Corrao G, Bertolaso G, Pavesi G, Moratti L
Int J Environ Res Public Health. 2022; 19(3).
PMID: 35162097
PMC: 8834613.
DOI: 10.3390/ijerph19031073.
Equitable access to COVID-19 vaccines makes a life-saving difference to all countries.
Ye Y, Zhang Q, Wei X, Cao Z, Yuan H, Zeng D
Nat Hum Behav. 2022; 6(2):207-216.
PMID: 35102361
PMC: 8873023.
DOI: 10.1038/s41562-022-01289-8.
Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy.
Corrao G, Franchi M, Cereda D, Bortolan F, Zoli A, Leoni O
Lancet Infect Dis. 2022; 22(5):649-656.
PMID: 35093194
PMC: 8797009.
DOI: 10.1016/S1473-3099(21)00813-6.
Return to normal pre-COVID-19 life is delayed by inequitable vaccine allocation and SARS-CoV-2 variants.
Liu F, Zhao Z, Ma C, Nie X, Wu A, Li X
Epidemiol Infect. 2022; 150:e46.
PMID: 35067231
PMC: 9058660.
DOI: 10.1017/S0950268822000139.
Seven-Month Analysis of Five SARS-CoV-2 Antibody Assay Results after ChAdOx1 nCoV-19 Vaccination: Significant Decrease in SARS-CoV-2 Antibody Titer.
Jeong S, Lee N, Lee S, Cho E, Hyun J, Park M
Diagnostics (Basel). 2022; 12(1).
PMID: 35054251
PMC: 8774861.
DOI: 10.3390/diagnostics12010085.
